Literature DB >> 20022440

Novel approaches using alkaline or acid/guanidine treatment to eliminate therapeutic antibody interference in the measurement of total target ligand.

Hossein Salimi-Moosavi1, Jean Lee, Binodh Desilva, George Doellgast.   

Abstract

Measurement of the total target ligand can help to provide pharmacokinetic (PK) and pharmacodynamic (PD) informations. However, the presence of monocloncal antibody therapeutics (ThAs) interferes with ELISA determinations of the total target proteins. The interferences can cause over- or under-estimation of the target protein analysis. The nature of interferences was dependent upon the ThA, target protein, antibody reagents and assay conditions of the ELISA. We have developed novel alkaline and acid/guanidine treatment approaches to dissociate the protein binding and preferentially denature the ThA. The neutralized target proteins can be determined by ELISA. These methods provide reproducible measurements of total target protein without ThA interference. Serum samples, standards and QCs containing target protein and ThA were treated with alkaline buffer (pH>13) containing casein or acid/guanidine buffer (pH<1). Total target proteins for two different ThA systems were successfully measured and interferences were completely eliminated by the treatments. These methods were successfully applied to analysis in pre-clinical serum samples. Copyright 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20022440     DOI: 10.1016/j.jpba.2009.11.021

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  8 in total

Review 1.  Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy.

Authors:  Narendra Chirmule; Vibha Jawa; Bernd Meibohm
Journal:  AAPS J       Date:  2012-03-10       Impact factor: 4.009

Review 2.  Bioanalytical approaches to quantify "total" and "free" therapeutic antibodies and their targets: technical challenges and PK/PD applications over the course of drug development.

Authors:  Jean W Lee; Marian Kelley; Lindsay E King; Jihong Yang; Hossein Salimi-Moosavi; Meina T Tang; Jian-Feng Lu; John Kamerud; Ago Ahene; Heather Myler; Cindy Rogers
Journal:  AAPS J       Date:  2011-01-15       Impact factor: 4.009

Review 3.  Theoretical considerations and practical approaches to address the effect of anti-drug antibody (ADA) on quantification of biotherapeutics in circulation.

Authors:  Marian Kelley; Ago B Ahene; Boris Gorovits; John Kamerud; Lindsay E King; Thomas McIntosh; Jihong Yang
Journal:  AAPS J       Date:  2013-03-30       Impact factor: 4.009

Review 4.  A white paper--consensus and recommendations of a global harmonization team on assessing the impact of immunogenicity on pharmacokinetic measurements.

Authors:  J M Sailstad; L Amaravadi; A Clements-Egan; B Gorovits; H A Myler; R C Pillutla; S Pursuhothama; M Putman; M K Rose; K Sonehara; L Tang; J T Wustner
Journal:  AAPS J       Date:  2014-03-29       Impact factor: 4.009

5.  Interrelationships between Infliximab and Recombinant Tumor Necrosis Factor-α in Plasma Using Minimal Physiologically Based Pharmacokinetic Models.

Authors:  Xi Chen; Debra C DuBois; Richard R Almon; William J Jusko
Journal:  Drug Metab Dispos       Date:  2017-04-14       Impact factor: 3.922

Review 6.  Modeling, simulation, and translation framework for the preclinical development of monoclonal antibodies.

Authors:  Kenneth T Luu; Eugenia Kraynov; Bing Kuang; Paolo Vicini; Wei-Zhu Zhong
Journal:  AAPS J       Date:  2013-02-14       Impact factor: 4.009

7.  The impact of immunogenicity on therapeutic antibody pharmacokinetics: A preclinical evaluation of the effect of immune complex formation and antibody effector function on clearance.

Authors:  Eugenia Opolka-Hoffmann; Gregor Jordan; Michael Otteneder; Robin Kieferle; Martin Lechmann; Gerhard Winter; Roland F Staack
Journal:  MAbs       Date:  2021 Jan-Dec       Impact factor: 5.857

Review 8.  Unraveling the Effect of Immunogenicity on the PK/PD, Efficacy, and Safety of Therapeutic Proteins.

Authors:  Alison Smith; Hugh Manoli; Stacey Jaw; Kimberley Frutoz; Alan L Epstein; Leslie A Khawli; Frank-Peter Theil
Journal:  J Immunol Res       Date:  2016-08-08       Impact factor: 4.818

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.